Thomas Eastling

Mr. Thomas W.
Eastling is a Chief Financial Officer at Gyre Therapeutics, Inc., a Chief Financial Officer & Director at Cullgen, Inc., a Chief Financial Officer, Secretary & Director at Berkeley Advanced Biomaterials, Inc., a Chief Financial Officer & Secretary at GNI USA, Inc., a Chief Financial Officer & Head-Investor Relations at Cullgen, Inc. (New) and a Member at National Association of Corporate Directors.
He is on the Board of Directors at Shanghai GEP Pharmaceuticals, Inc., Cullgen, Inc., Berkeley Advanced Biomaterials, Inc., GNI Hong Kong Ltd., Shanghai Genomics, Inc., Continent Pharmaceutical, Inc. and GNI Group Ltd. Mr. Eastling was previously employed as a MD-Strategic Planning & Investor Relations by SoftBank Mobile Corp., a Managing Director by Fitch Group, Inc., a Managing Director & Senior Vice President-Japan by Duff & Phelps Credit Rating Co., and an Independent Director by Kai Wo Asset Management Ltd. He also served on the board at Catalyst Biosciences, Inc. He received his undergraduate degree from the University of Southern California and a graduate degree from Thunderbird School of Global Management.